Biotechnology Firm Reveals Breakthrough Discovery For Anti-cancer Treatment

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology firm dedicated to developing innovative treatments for oncological and inflammatory diseases, has unveiled new findings concerning its small molecule drug, Namodenoson. These recent discoveries shed light on the mechanisms by which Namodenoson exerts both anti-cancer and liver-protective effects through the regulation of adiponectin, a crucial signaling protein. $Can-Fite BioPharma (CANF.US)$